(News Bulletin 247) – Janssen Pharmaceutical Companies of Johnson & Johnson today announced long-term data from the pivotal Phase 1/2 MajesTEC-1 study’ showing the continued efficacy and safety of Tecvayli ( teclistamab-cqyv) in the treatment of patients with relapsed or refractory multiple myeloma (RRMM),’ reports J&J.
These results showed that nearly half of the patients achieved a complete response (CR) or better, ‘underscoring the durable and continued responses seen in this patient population,’ the company continues.
The study’s extensive follow-up data demonstrates an overall response rate (ORR) of 63%, with responses continuing to deepen over time.
Over 45% of patients now achieved CR or better, and the median time to CR or better was 4.6 months. The minimal residual disease negativity rate at day 100 from the first dose of Tecvayli in evaluable patients was 81%.
“Our results further support the role it can play in treating patients with relapsed or refractory disease,” said Niels van de Donk, MD, professor of hematology at University Medical Centers Amsterdam, and researcher principal of the study.
Copyright (c) 2023 News Bulletin 247. All rights reserved.
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
